Guillain-Barré syndrome

Guillain-Barré syndrome (GBS) occurs when the immune system attacks part of the nerves in the peripheral nervous system. Below are COVID news and research updates that specifically relate to GBS.

Occurrence of Autoimmune Diseases following COVID-19

COVID-19 and autoimmune disease share some similarities regarding molecular mechanisms of diseases. The authors of a paper published in November 2022 suggest that drugs used to treat autoimmune patients can serve as a potential treatment for COVID-19 patients.

Read More »

Can a COVID Infection Trigger GBS?

Cases of GBS have been verified by the FDA as a rare side effect to certain vaccines, including Johnson & Johnson’s COVID-19 vaccine. GBS has also been known to develop after certain respiratory or gastrointestinal viral infections and may be triggered by a COVID-19 infection. 

Read More »

Can GBS Return Following COVID Vaccination?

A research letter, published in JAMA Network last week, studied the rate of recurrent Guillain-Barré Syndrome (GBS) following vaccination with the mRNA Pfizer-BioNTech COVID-19 vaccine and found the risk to be extremely low. This retrospective cohort study utilized medical data from the second largest health maintenance organization in Israel

Read More »
Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.